Fate Therapeutics, Inc. (FATE) financial statements and ratios from SEC XBRL: revenue $6.65M (TTM), net margin -2051.1%, revenue growth -51.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $6.65M |
| Net Margin | -2051.1% |
| Revenue Growth (YoY) | -51.2% |
| EPS Growth (YoY) | -29.9% |
| FCF Growth (YoY) | -9.4% |
| Price / Book | 1.81 |
| Price / Sales | 43.29 |
| FCF Yield | -62.4% |
| Altman Z-Score | -6.14 (distress) |
| Sector P/E (Healthcare) | 21.7 |
FATE overview · FATE earnings · FATE KPIs · FATE investor relations · FATE ownership · FATE peers · FATE filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.